Novartis AG (NVS) — Stock Price, Chart & Analysis
Novartis AG (NVS) is a Healthcare stock currently trading at $141.28, up 0.21% on the day. It carries a market capitalization of $268.53B and a trailing P/E ratio of 21.28. Over the past 52 weeks, NVS has traded between $121.57 and $170.46. Novartis AG pays a dividend yielding 3.4%. View the live NVS chart, technical opinion, analyst ratings, fundamentals and latest news below.
Novartis AG (NVS) key data
| Price | $141.28 |
| Change (today) | +0.21% |
| Previous close | $140.98 |
| Market cap | $268.53B |
| P/E ratio (TTM) | 21.28 |
| EPS (TTM) | $6.64 |
| Dividend yield | 3.4% |
| 52-week high | $170.46 |
| 52-week low | $121.57 |
| Beta | 0.49 |
| Avg. volume | 2.10M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Frequently asked questions about Novartis AG (NVS)
How much does one share of Novartis AG cost?
As of the latest update, one share of Novartis AG (NVS) trades at $141.28 (+0.21% today).
What is Novartis AG's market cap?
Novartis AG has a market capitalization of approximately $268.53B.
What is Novartis AG's P/E ratio?
Novartis AG has a trailing price-to-earnings (P/E) ratio of 21.28.
What is Novartis AG's earnings per share (EPS)?
Novartis AG's trailing twelve-month EPS is $6.64.
Does Novartis AG pay a dividend?
Yes — Novartis AG pays a dividend with a yield of 3.4% ($4.74 per share annually).
What is Novartis AG's 52-week trading range?
Over the past year, NVS has traded between $121.57 and $170.46.
What is the analyst price target for Novartis AG?
The mean analyst price target for Novartis AG is $156.29. This is informational only and not investment advice.
Latest Novartis AG (NVS) news
- Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing RaceNews · Sep 23, 2026
- BoomRay and Novartis sign $900m deal for radioligand therapyNews · Sep 23, 2026
- Capitalize on the Orphan Drug Revenue Shift: Benchmark Novartis, Roche, Pfizer, Sanofi and AstraZeneca to Secure High-Value Growth Before Rivals Move FirstNews · Sep 22, 2026
- BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy AssetNews · Sep 22, 2026
- Morgan Stanley flags Amgen's edge after heart-drug rival stumblesNews · Sep 22, 2026
- Telix Beefs Up Radioisotopes Supply With $2.35 Billion Deal; Shares CrashNews · Sep 21, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live NVS dashboard…